# Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

> **NCT04531163** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Al-Azhar University** · enrollment: 60 (actual)

## Conditions studied

- Diabetic Kidney Disease
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies

## Interventions

- **DRUG:** N Acetylcysteine

## Key facts

- **NCT ID:** NCT04531163
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2020-11-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531163, "Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04531163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*